Vertaile menetelmiä

	Potilasarvio ummetuksen laadusta elämässä	Gastropareesi Kardinaalioireiden Indeksi	Roomalaiset IV -diagnostiikkakriteerit ärtyvän suolen oireyhtymälle
Tieteenala	Gastroenterologia	Gastroenterologia	Gastroenterologia
Menetelmäperhe	Process / pipeline	Process / pipeline	Process / pipeline
Syntyvuosi	2005	2003	2016
Kehittäjä	Marquis, P., De La Loge, C., Dubois, D., et al.	Revicki, D. A., Rentz, A. M., Dubois, D., et al.	Rome Foundation (multinational expert consensus)
Tyyppi	Self-report	Self-report	Diagnostic Criteria
Alkuperäislähde	Marquis, P., De La Loge, C., Dubois, D., McDermott, A., & Chassany, O. (2005). Development and validation of the Patient Assessment of Constipation-Quality of Life questionnaire. Scandinavian Journal of Gastroenterology, 40(5), 540–551.	Revicki, D. A., Rentz, A. M., Dubois, D., Kahrilas, P., Stanghellini, V., Talley, N. J., & Tack, J. (2003). Development and validation of a patient-assessed gastroparesis symptom severity index. Alimentary Pharmacology & Therapeutics, 18(1), 141–150.	Mearin, F., Lacy, B. E., Chang, L., et al. (2016). Bowel disorders. Gastroenterology. Published online June 2016 by the Rome Foundation.
Rinnakkaisnimet	PAC-QoL, PAC-Q	GCSI	Rome IV IBS, Rome Criteria
Liittyvät	4	4	4
Tiivistelmä	The Patient Assessment of Constipation Quality of Life (PAC-QoL) is a validated, patient-reported outcome measure designed to assess the impact of functional constipation on physical, psychological, and social well-being. Developed by Marquis and colleagues in 2005, the PAC-QoL comprises 28 items organized into four domains: Physical Discomfort, Psychosocial Discomfort, Worries and Concerns, and Satisfaction. The PAC-QoL is responsive to treatment and widely used in constipation clinical trials and practice.	The Gastroparesis Cardinal Symptom Index (GCSI) is a validated, patient-reported outcome measure specifically designed to assess symptom severity in gastroparesis. Developed by Revicki and colleagues in 2003, the GCSI captures the three cardinal symptom clusters of gastroparesis: nausea and vomiting, postprandial fullness, and early satiety, plus bloating and stomach distension. The 9-item questionnaire is responsive to treatment changes and is increasingly used in clinical trials and practice to monitor gastroparesis progression and therapy response.	The Rome IV criteria are the internationally accepted diagnostic standard for irritable bowel syndrome (IBS), published in 2016 by the Rome Foundation. These criteria define IBS as recurrent abdominal pain (≥1 day per week for ≥3 months) associated with altered bowel habits, without structural or biochemical abnormalities. IBS is subtyped into four patterns—IBS-constipation predominant (IBS-C), IBS-diarrhea predominant (IBS-D), IBS-mixed (IBS-M), and IBS-unclassified (IBS-U)—based on stool consistency patterns.